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Percutaneous intervention therapyDespite revolutionary advancement inmedicine over the past century, cardiovascular disease (CVD) remains the
leading cause of death and disability in the world. Likewise, the morbidity and mortality of CVD in China are
increasing persistently, although the government has taken an active part in the prevention and control of
CVD.Herewe present an overview regarding the current CVD status in Chinawith respect to various disease phe-
notypes, as well as the anticipated future trend in accordancewith the dynamics and distribution of pathogenesis
in Chinese actual situations.
© 2014 Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
In the last 30 years, the rapid development of economy and medical
science in China has led to a drastic improvement in public health; the
average life span has been extended steadily and signiﬁcantly year
after year. In contrast, cardiovascular relevant morbidity and mortality
in Chinese population rose quickly; in particular, the age of patients is
becoming younger. It is estimated in the “Report on Cardiovascular Dis-
ease in China, 2011” that there are about 230million patients with CVD,
including 200 million patients with hypertension, 7 million patients
with stroke, 2 million patients with myocardial infarction, and 4.2
million patients with heart failure. There are 3 million cases of death
of CVD each year, accounting for 41% in total. However, delightedly, it
is noticed that government sector is perfecting public health policy
and law further, increasing research and capital investment [1] (Fig. 1)
in this sector, and that the public health sense is being upgraded
gradually.2. Cardiovascular risk factors
The upwards tendency of the proportion of patients with CVD in
China were closely associated with the increased number of cardiovas-
cular risk factors (e.g., hypertension [2], smoking [3], dyslipidemia [4],
diabetes [5,6], overweight [7], obesity [7] and metabolic syndrome
[8,9], et al.) (Fig. 2) and population ageing. It is known that there are ap-
proximately 300 risk factors of CVD, meanly including dyslipidemia,
smoking, hypertension and diabetes [10]. When multiple factors are atovascular Diseases, Zhongshan
i 200032, China. Tel.: +86 21
is an open access article under the Cco-existence, the effects are augmented and exacerbated; which result
in accelerated CVD development and increased mortality. Therefore,
programs delivering comprehensive management of risk factors for
CVD are essential when we optimize the distribution of medical
resources to overcome this national health challenge.
Based on the “Chinese Inhabitants Nutrition andHealth Examination
Survey in 2002” [11], the result showed that the prevalence rate of adult
hypertensionwas 18.8%, higher inmales than in females andmore com-
mon in the north area than in south area; the awareness, treatment and
control rates of patients with hypertension were 30.2%, 24.7% and 6.1%
respectively, which was lower than that of developed countries. Anoth-
er survey [12] showed that about 2.33 million CVD deaths were related
to hypertension in 2005. In order to strengthen the guidelines for pa-
tients with hypertension and high-risk individuals involved in this dis-
ease, the Chinese government implemented the large management
program for this patient population in 2009, with the total number
enrolled reaching more than 35 million in 2010. To provide the
evidence-based medicine to optimize the pharmacologic therapeutic
regimen for hypertension, clinical studies focusing on this topic (Syst-
China [13,14], FEVER [15] et al.) were conducted continuously in
China. Recently, CCBs was recommended as a preferred drug for
themanagement of hypertension in China to improve blood pressure
control and to confront the aggravating epidemic of stroke and
coronary heart disease [16]. As for the deﬁnite basic and standard hy-
potensive targets, based on former researches, “Guidelines for Pre-
vention and Treatment of Hypertension in China” was promulgated
in 2010. In parallel to routine application of antihypertensive medi-
cine, percutaneous stent implantation for hypertension caused by
renal arterial stenosis and catheter-based renal sympathetic dener-
vation (RSD) (RSD were adapted to treat the ﬁrst patient in China
in Fuwai Hospital, Beijing in February, 2012), as well as Baroreﬂex
activation therapy [17] might have gained widely clinical prospectC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Fig. 1. A Data from China Statistical Yearbook 2011 indicates the health expenditure of China from 2001 to 2009. Total health expenditure, government health expenditure, social health
expenditure, and individual health expenditure as well as per capital health spending were on the increase year by year from 2001 to 2009 and total health expenditure and per capital
health spending in 2009 were more than 3 times that in 2001, whereas government health expenditure in 2009 rose to over six times than that in 2001. Fig. 1B & C shows that the
proportions of health expenditure had changed signiﬁcantly between 2001 and 2009. In 2001, 60% of total health expenditure was taken up by an individual sector; in 2009, more
than 60% of its ﬁnance came from the government and social sectors.
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their treatment for refractory hypertension.
Smoking is a second main risk factor of CVD and stroke in Chinese
population [18], and the detrimental impact of smoking and passive
smoking is considered as equally harmful to public health. The “Global
Adult Tobacco Survey (GATS) — China section” in 2010 indicated that
52.9% of men, 2.4% of women, and 28.1% of the overall population
(301million adults aged over 15) currently smoke tobacco; 7 in 10 non-
smoking adults were exposed to secondhand smoke in a typical week;
only 46.4% of adults noticed anti-cigarette smoking information on the
television or radio; and 23.2% of adults believe smoking causes stroke,
heart attack, and lung cancer. Among the various smoking subpopula-
tions in China, there is a noticeable increase in the younger age and
the female groups. Accordingly, a series of measures have been adopted
by the Chinese government to reducing its harmful impact; nationallegislations on smoking ban in all public domains came into effect in
2011.
The “National Investigation of Adult Lipid Abnormality” in 2002
showed that prevalence rate of dyslipidemia was 18.6%, with 2.9%
hypercholesterolemia and 11.9% hypertriglyceridemia [19]. The “China
Cholesterol Education Program” [20] (CCEP) in 2008 indicated that the
success rate of LDL-C management in high-risk patients and very
high-risk patients were 36.2% and 42.2% respectively. These results are
promising; they are credited to the rigorous lipid-reduction therapeutic
programs in both prevention and management of the disease situation,
which are widely taking place in China. Based on previous large-scale
epidemiological surveys and clinical investigations, the different criteria
of serum cholesterol levels and the target value with regulating lipid
drugs in Chinese population have been deﬁned. Cardiovascular residual
risk [21–23] began to attract considerable attention of scholars and
Fig. 2. Presented the prevalence of CVD risk factors: hypertension, smoking, dyslipidemia, diabetes, overweight, obesity and metabolic syndrome, in Chinese population. Besides the
prevalence of smoking which had declined since 1996, all that remains showed a rising trend: that of dyslipidemia, diabetes, and metabolic syndrome with strong upward trend; that
of hypertension, overweight, and obesity being moderately increasing.
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nal combined therapy for lipid control had beenmore effective than that
in the treatment with any singular reagent; for example, Ezetimibe in
combination with statins, have offered tremendous success to improve
total cholesterol, LDL-C, non-HDL cholesterol, and apolipoprotein B in
several reports [6,24].
From 2007 to 2008, the Chinese Medical Association Diabetes
Branch (CDS) conducted a national survey [25] of diabetes in several
large cities in China and demonstrated that the average prevalence
rate of diabetic patients was 9.7%, with higher occurrences in males
than in females; the rate in the urban and in the rural populations
were 11.4% and 8.2%, respectively. Due to the recent population aging
and overweight issues in China, more than 95% diabetic patients were
patients with type II diabetes mellitus. A follow-up study [26] that has
been ongoing for 20 years, with evidence-based investigations, illustrat-
ed that life style intervention (rational diet, proper exercises andweight
control et al.) in Chinese population had a demonstrable effect to
prevent diabetes (43% versus 66%). However, it was noted that a sig-
niﬁcant subpopulation of Chinese CVD patients are hyperglycemic,
per a report by “China Heart Survey” in 2006 [27]. In view of this sce-
nario, many of them are recommended to undergo individualized
glucose-lowering therapy [28–31]. With the recent advancement in
insulin therapy, patients with diabetes mellitus will beneﬁt from
the newly marked oral or inhaled administration of encapsulated
insulin nano-particles with bioﬁlm in the near future, which could
get rid of present quandary.
A national survey [7] in 2002 was conducted and the data was ana-
lyzed that the prevalence rates of overweight and obesitywere at an un-
precedented stage; they were 22.8% and 7.1%, respectively. To address
this urgent national issue, “Dietary Guidelines for Chinese” was pub-
lished in 2007 and subsequently, an updated version was released
2011 [32,33]. These guidelines recommend that daily nutrition intake
should compose 55–65% of calories as carbohydrate, 20–30% as fat and
11–15% as protein. The concept of metabolic syndrome (MS) was ﬁrst
put forward by CDS in 2004. According to an investigation [34],
prevalence of MS in the population group aging from 35 to 74 years
old was 16.5%, which is also more prominent in females than males
(23.3% versus 10.0%); the occurrence is much higher in the urban resi-
dents than in the rural populations (23.5% versus 11.7%). A dietary inter-
vention study [35] demonstrated that accompanying the rising number
of metabolic risk factors, salt sensitive high blood pressure in non-diabetic people in China was increased. Life-style has again, shown to
be important for CVD management. The analysis of related risk factors
in Chinese population with MS [36] indicated that the prevalence rate
of MS could be attenuated by moderate physical activity. It is gradually
recognized that MS is a series of diseases with high correlation to
patient life-style. The intervention on life style is of equal importance
to blood glucose control, blood lipid adjustment and antihypertensive
therapy.
3. Coronary heart disease
Information presented in the “China Health Statistics Annuals in
2009” indicated that coronary heart disease mortality rate of urban
residents in 2008 was about 91.41 out of 100,000 examined, with
51.89 out of 100,000 surveyed in the rural residents. Due to the in-
creased incidence of coronary heart disease in recent years, therapies
on coronary heart disease developed continuously. Anti-anginal drug
and anti-metabolites (e.g., trimetazidine) had been suggested for
combined applications onmyocardial ischemia, in addition to drugs im-
proving hemodynamics. Statin Drugs (Atorvastatin) was also approved
to treat CVDdirectly in 2010. Urokinasebe is being gradually replaced by
recombinant tissue plasminogen activator (rt-PA) as the preferred
treatment for thrombolysis in China, especially in the geographical loca-
tions lacking emergency support for percutaneous coronary interven-
tion (PCI).
Overall, revascularization of coronary artery by intervention is
routinely the primary choice for patients with ST segment-elevation
myocardial infarction (STEMI) as well as the main approach of invasive
therapy for patients with acute coronary syndrome (ACS) in China. The
past three decades alsomarked enormous progress and rapid growth at
the forefront of invasive therapy. Since the ﬁrst percutaneous translu-
minal coronary angioplasty (PTCA) was performed in Suzhou, China in
1984, the total number of PCI in China reached 180,000 procedures in
2007 [37], and then it nearly doubled again in less than four years,
when the number of procedures was recorded as 330,000 in 2011. The
ever-increasing demand for invasive therapy has facilitated the innova-
tion and creation of cardiovascular device industry in China. Running
parallel with Medtronic, Boston Scientiﬁc, Guidant Abbott, and B.
Braun in the Chinesemedical devicemarket, aremore than six domestic
products that have been applied successfully in clinics throughout
China; including stents from Lepu Medical Technolog, MicroPort
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statistics in 2006, more than 95% patients were treated with drug-
eluting stents (DES) [38]; among those, more than 70% were domestic
DES thus far, including durable polymer DES, bio-absorbable polymer
DES and polymer free DES. In addition, our preclinical study of fully
bio-absorbable PLLA coronary stent- Xinsorb™ has shown promising
results [39]; and large-scale clinical studies are soon to be launched. In
the past decades, technological innovations of PCI relevant methods
have elevated cardiovascular therapy to a new horizon in China. To en-
hance the success rate of recanalization of chronic total occlusion (CTO),
Chronic Total Occlusion Club, China (CTOCC) was established in
Shanghai in August, 2005. In October, 2005, kissing wire technique
was ﬁrstly demonstrated in live case transmission of TCT, Washington
DC. Recently, retrograde approaches for CTO PCI have become popular
in many centers. However, according to results from a multicenter
trial and prospective study analyses in China [40], a total of 2901 pa-
tients with acute coronary artery syndrome (ACS) were surveyed and
the majority of them (45%) were SETMI, whereas 12% of them were
non-STEMI. Compared to other developed countries in the western
world, Sino-GRACE study [41] showed that the rate of primary PCIwith-
in 90 min and thrombolytic therapy within 30 min for the treatment of
acute myocardial infarction is considerably lower in China. Door-to-
balloon time of primary PCI in China is longer than that in developed
countries. One contributing reason might be related to the distribution
of economic status and medical resources in China. Great efforts have
been made to improve health care nationwide; training/education pro-
grams for diagnosis and treatment of CVD by intervention have been
launched and implemented by the Chinese Ministry of Health in 2009.
Among the many challenges, improving reperfusion therapy for pa-
tients with AMI via PCI or thrombolytic therapy within “the therapeutic
window” has been the center of focus. Signiﬁcant progress has been
made in several areas with rewarding outcomes; for example, clinical
application of anticoagulation and antithrombotic therapy in primary
PCI for patients with ACS, combined application of distal protection de-
vice, thrombus aspirated catheter, intra-aortic balloon counterpulsation
or extracorporeal membrane oxygenation when necessary, had made
post-PCI mortality decrease signiﬁcantly, and the relevant prognosis in
post-PCI cardiogenic shock improved remarkably in recent years.
China has also led a pioneer effort on stem cell therapy for STEMI;
preliminary studies using bone marrow stem cell transplantation dem-
onstrated study feasibility as well as moderate improvement in cardiac
function during early treatment. Future investigations are required to
delineate the destinations and mechanistic actions of these stem cells.
4. Heart failure
Longitudinal analyses of several CVD patient populations were re-
ported in 1980, 1990, and 2000; these studies showed that the hospital-
ization rate of patients with heart failure was 16.3%–17.9% for CVD
patients, with more than 60% of patients being over 60 years old, and
the improvement rates of symptom were 15.5%, 19.6% and 22.2%, re-
spectively [42]. Comparison analyses of all major causes of heart failure
in China revealed an interesting trend; CVD (45.6%) ranked number one
in 2000, followed by rheumatic valvular disease (21.0%) [42]. This order
was reversed in 1980; when rheumatic valvular disease was the
number one cause of death three decades ago.
Brain Natriuretic Peptide (BNP), also known as the B-type natriuretic
peptide, has been adapted successfully in Chinese cardiovascular medi-
cine; it has been gradually becoming an important clinical standard
marker for the diagnosis of heart failure in patients, even in the absence
of symptom or clinical evidence of CVD. The recombinant form of
human B-type natriuretic peptide (Xin huo su) in China was approved
to treat heart failure in 2005, which has displayed consistent and
beneﬁcial effects, including vasodilatory, natriuretic, diuretic, and
neurohormonal effects. The rh-BNP phase IV clinical trial in China,
consisting of 9 centers nationwide from 2008 to 2009, has achieved arewarding outcome. Their reports demonstrate that clinical manifesta-
tion of heart failure was signiﬁcantly improved in the majority of 1493
patients enrolled in the trial and per trial studies presented at the 20th
Great Wall International Congress of Cardiology. In 2003, Delle Karth
G et al. [43] reported that Levosimendan (LS) infusion is feasible and
able to improve hemodynamics in severely compromized, critically ill
patients with cardiogenic shock requiring catecholamine therapy. In
2010, a domestic inotropic and vasodilator agent (YueWen) was ap-
proved for clinical applications. YueWen is a calcium sensitizer; which
functions to increase the sensitivity of the heart to calcium, thereby
augmenting cardiac contractility without impacting the intracellular
calcium levels. The control rates of β-receptor blockers in the treatment
of heart failure was low in China in the past few years, so attaining
necessary target dosage has become an exigent and necessary mission
in the next few years.
The ﬁrst cardiac resynchonization therapy (CRT) device was applied
in China in 1999. To date, more than 4000 heart failure patients were
treated with CRT or CRT + ICD. It is believed that a considerable
population of Chinese patients with refractory heart failure will beneﬁt
from it. One issue requires special attention is under the scenario where
patients are diagnosed with atrial ﬁbrillation co-existing with ventricu-
lar asynchrony; this group could beneﬁt from CRT therapy, per prelim-
inary studies, however, their safety and effectiveness still require
further evaluations by large-scale clinical trial. Over the past decade,
theChinese cardiologists have exhibited tremendous courage in creativ-
ities and innovations. In October, 2010, ZhongshanHospital at Shanghai,
accomplished the very ﬁrst case of percutaneous aortic valve implanta-
tion (TVAI) in China [44]; the success of this exceptionally challenging
procedure pioneered the Chinese TVAI program and advanced the
Chinese cardiac non-invasive therapy to a new level. In May, 2012, a se-
vere mitral regurgitation patient was successfully treated with
MitraClip via femoral vein catheterization in the same hospital in
Shanghai, representing another major milestone in non-invasive thera-
py in China. Giving the prevalence of rheumatic heart diseases is much
higher in China than that in the western countries; the success of
these procedures is of great signiﬁcance. A large number of valve disease
patients are anticipated to beneﬁt from this new procedure; in particu-
lar, this non-invasive procedure will help the large aging patient popu-
lation in China. The percutaneous transseptal ventricular assist system
was originally designed as a short-term circulatory support system for
patients with end-stage heart failure. The assisted devices, for example,
Tandem and Impella, had been successfully applied to clinic therapy
elsewhere for over a decade now; however, they have not made their
way to the therapeutic market in China. Despite its complication and
LVAD is not recommended to be the ﬁrst choice of mechanical therapy
for patientswith cardiogenic shock [45], it is anticipated that percutane-
ous circulatory support technology would be an important future direc-
tion for Chinese cardiovascular therapy, pending regulatory and policy
issues to be resolved.
5. Arrhythmia
Artiﬁcial pacemakers had been administered as therapies to patients
with an abnormal heart beat pattern for at least half century. The ﬁrst
cardiac pacemaker was implanted into a patient in China in 1962. In
2006, the total pacemaker cases reported were more than 20,000 [46].
In August, 2012, transseptal endocardial left ventricular pacing was
ﬁrst performed in Zhongshan Hospital, Shanghai.
Two decades ago, radiofrequency catheter ablation (RFCA) became
an approved procedure to correct disturbances in heart rhythm in
China; the ﬁrst RFCA case was reported in 1991. According to statistic
data published in 2000, 56.3%of patients underwent RFCAhad atrioven-
tricular nodal reentrant tachycardia (AVNRT), and 31.7% of them were
diagnosed of atrioventricular reentrant tachycardia (AVRT). In 2006,
RFCA cases reached 20,000 [46]. This case number has steadily increased
in recent years. Among them, patients who underwent atrial ﬁbrillation
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these procedures had a success rate of 77.1%, a recurrence rate of 22.9%
and a complication rate of 22.9%[47]. In 2004, a population study on atri-
al ﬁbrillation (AF) [48] surveyed 29,079 residents in 14 provinces and
cities in China; the results indicated that the total prevalence rate of pa-
tients aging from 30 to 85was 0.77%;whichwas higher inmales than in
females. Furthermore, a recent multicenter registry study [49] in 2008
showed that the average age of patients with AF was (57.4 ± 1 1.4)
years, and the proportions of paroxysmal, persistent and permanent
AFwere 71.5%, 22.8% and 5.7%, respectively; 47.2% of which had organic
heart diseases. The primary therapeutic procedures were circumferen-
tial pulmonary vein isolation and circumferential PV isolation plus nec-
essary atrial auxiliary line; the energy applied for catheter ablation was
radiofrequency, which had an 82.1% success rate and a 17.9% recurrence
rate; the overall rate of complicationswas 1.7%. The signiﬁcant progress
towards the understanding on the underlying pathogenesis of AF
[50–52] combinedwith the continuous advancement of radiofrequency
ablation techniques (e.g., the circular cryoablation catheter and the
magnetic navigation system), have drastically improved the success
rate for this procedure.
Parallel to technological improvement of radiofrequency ablation
(RFA), new drug discovery during the last few years has also optimized
the treatment strategy for AF. Despite this, the successful translation of
these therapies to clinical applications remains limited. An epidemio-
logical analysis in 2004 [53] revealed that 60% of patients with AF did
not receive any anticoagulation therapy. As a preferred drug, Warfarin
was only applied to 7.1% patients with non-valvular AF according to
data fromFuwai Hospital in 2007. The causes contributing to this barrier
are not entirely clear but may be attributed by the adversary effects of
Warfarin (e.g., bleeding). Recently, Aspirin combined with Clopidogrel
were recommended as substitutes for Warfarin to treat patients who
can't or will not accept the latter in China. However, a large clinic trial
[54] indicated that the effect of anticoagulation therapy with Aspirin
combined with Clopidogrel was inferior to that with Warfarin. These
ﬁndings necessitate the introduction of novel anticoagulant drugs and
exigent its development in China. There have been reports on strong
candidates for new AF therapies outside of China. Dabigatran
(Boehringer Ingelheim), also known as the direct thrombin inhibitors,
was granted marketing authorization by European Medicines Agency
in 2008. RELY [55] showed that it could offer an alternative to warfarin
as the preferred orally administered anticoagulant to prevent strokes in
patients with atrial ﬁbrillation. Dabigatran is viewed to have a broad
clinical prospect for the management of AF in China; in some cases,
this drug is likely to reach an impact similar to Aspirin; which has
been recommended as the most effective anti-platelet therapy with
best effect/risk ratio in all clinics [56]. In view of the respective advan-
tages offered by the pharmacologic treatment or mechanical therapies
(e.g., ablation), a large-scale comparative clinical trial differentiating
the susceptibility and sensitivity of the patient populations on these
two approaches is required to further optimize therapy and to enhance
its success rate for AF patients in China.
For patients with AF as well as combined high-risk thrombus fac-
tor with a contraindication for oral anticoagulation treatment, per-
cutaneous left atrial appendage transcatheter occlusion (PLAATO)
has been recently applied as an alternative and feasible approach
in preventing embolism. Meanwhile, for patients with paroxysmal
or lone AF exhibiting low susceptibility to both pharmacological
and procedure based therapies, minimally invasive surgery has
been successfully performed in recent years; the thoracoscopic
based procedures may gradually replace the conventional maze pro-
cedure for chronic AF in China. In addition to all listed above is the
rise of stem cells (SCs) based therapy for AF; common to its challenges
in other ﬁelds, the clinical studies applying stem cells to treat arrhyth-
mia still face difﬁculties pertaining to the optimization of transplanta-
tion methods, the modiﬁcation of SCs, and the directed differentiation
of SCs.6. Congenital heart disease
Congenital heart disease (CHD) is the most common pediatric heart
disease, and the detection rate of infants with CHD is about 0.7% in
China. It is estimated that there are almost 150,000–170,000 Chinese
newborn infants with CHD every year [57]. Surgical ligation of patent
ductus arteriosus was ﬁrstly reported to carry out in China in 1942,
with atrial septal defect repair under cardiopulmonary bypass in 1956.
The total number of cardiac surgical procedures was over 80,000 in
2004, among which, 60%–65% was related to CHD [57]. Balloon atrial
septostomywas carried out in the1970s,whichmarks the earliest inter-
ventional therapy for CHD in China. In themiddle of the 1980s, the tech-
nology has matured; interventional therapy for CHD had been applied
broadly in clinical treatment; since that time, the techniques have
been rapidly popularized itself throughout China. It remains as the pri-
mary choice in some cases till today; it has been proven to be especially
beneﬁcial following clinical application of domestic occluder device.
Y.W. Qin and colleagues (Changhai Hospital, Shanghai) conducted a
review [57] on CHD in China in 2005; they report that more than 4500
individuals underwent CHD relevant interventional therapy in 2004.
The statistic analysis indicated that 9311 ventricular septal defect
(VSD) cases were treated with transcatheter closure of VSD within 21
hospitals in 2007, with 96.45% success rate and 2.61% complication
rate as well as 0.05% mortality. For patients with complex congenital
malformations, the availability of hybrid cardiovascular suite undoubt-
edly brings renewed hope; as this approach integrates the intervention-
al techniques into thoracic operations; it is likely to play a vital role for
cardiovascular surgery [58]. From 2009 to 2010, the Chinese Ministry
of Health reported that a total of 34,693 CHD cases, including atrial sep-
tum defect, ventricular septum defect and patent ductus arteriosus,
were treated percutaneously; The overall successful rate was 97.24%–
97.67%, with 0.90%–0.92% complications rate, and 0.03%–0.05%
mortality rate [59]. Giving the identiﬁed risk as well as other
uncertainties surrounding the implantation of metal framework in the
body, advancement of biodegradable occluder has become a key future
development trend in China. With the rapid growth of omics technolo-
gies in personalized medicine, gene chips and protein chips will be
available to identify markers indicative of high risk for CHD in China,
affording new opportunities to aid the stratiﬁcation of therapeutic
regiments for CHD.
7. Stroke
Historically, China has had high susceptibility for stroke. Compared
to western countries, the stroke incidence in Chinese population is
universally higher and the etiology of acute stroke investigated in
China is distinct, mainly triggered by intracranial atherosclerotic steno-
sis. At present, stroke is ranked as the second leading cause of death in
China. According to the statistics of a national survey, the annual
incidence rate and annual mortality rate of cerebrovascular diseases in
the large cities were 219/100,000 and 116/100,000, respectively,
which corresponds to 185/100,000 and 142/100,000 in the countryside;
regional and gender differences are also noted; stroke is more common
in the northern part of China compared to the southern areas, it is
higher in males than in females. Mortality trend of cerebral infraction
is increasing gradually, whereas that of cerebral hemorrhage is decreas-
ing. Many studies optimizing pharmacological therapy in China were
performed twenty years ago. Post-stroke antihypertensive treatment
study (PATS), which represents the ﬁrst large-scale antihypertensive
therapy for stroke research was accomplished independently in China
from 1991 to 1994, demonstrating that the recurrent stroke rate has
been reduced by 31% amid the beneﬁcial treatment of diuretics.
Perindopril protection against recurrent stroke study (PROGRESS)
which was an internationally organized, large-scale and multi-center
based clinical trials included 1520 Chinese patients from 1995 to 2001.
The outcome indicated that Perindopril is beneﬁcial for secondary
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study [60] showed that all-cause death rate and recurrent cerebrovascu-
lar events in adult patients were decreased by antiplatelet therapy. In
recent two decades, percutaneous neural interventional treatment has
been gradually becoming an important means for non-drug therapy of
cerebrovascular disease in Chinese population. Although the interven-
tional neuroradiology (thrombectomy or thrombolysis of hyperacute
cerebral infarction, stenting of extra- and intra-cranial artery stenosis,
interventional embolization of cerebral aneurysm or arteriovenous ﬁs-
tula, etc.) in China began at amuch later time than that in the developed
countries, China has undergone a rapid growth phase in many aspects
regarding stroke therapy in the last decade.
8. Lower extremity arterial disease
From 2003 to 2008, ﬁve investigations in different areas of China
were conducted and the data were analyzed that: among the 29,406
adults studied who are aged over 18, the prevalence of lower extremity
arterial disease (LEAD) in natural population was 6.2%; among the
population with diabetes and metabolic syndrome, the incidence was
up to 38.7% and 45.1%, respectively. Gender difference was also
detectable; with higher occurrence in females than inmales. Correlative
analysis based on the epidemiological study in Beijing area [61,62]
showed that there was a signiﬁcantly positive correlation between the
occurrence and the severity of LEAD with risk factors, including age,
smoking, diabetes, high systolic blood pressure and high low-density
lipoprotein cholesterol. In particular, approximately 25% patients with
ischemic heart disease suffer from their coexisting LEAD [61,63]. In
2008, the survey [62] of peripheral vascular disease (PAD) in Chinese
natural population showed that the overall prevalence of PAD
was 3.08%, whereas it was 2.52% in males and 3.66% in females; the
prevalence of PAD was signiﬁcantly increased with age in population
(P b 0.01). The clinical application of interventional techniques in
China has revolutionized therapeutic concepts and approaches on pre-
viously challenging cases, where routinely-administered drugs for
LEAD patients had become ineffective, thereby overcoming quandary
in many aspects of those patients with severe symptoms and avoiding
revascularization by surgical method in recent years.
9. Expertise and workforce in Chinese cardiovascular medicine
Recently, the Chinese government has placed large resources into
the education and training of the work force in various sectors of public
health. These investments have shaped an expert team to combat the
cardiovascular disease challenges facing the nation. A survey [64] in-
cluding 25,240 doctors specializing in cardiovascularmedicine through-
out China indicated their average age as 38 years old, among them are
58.5% males; their average practicing time post obtaining license was
12 years, approximately 40.4% of them host a senior academic title
and 33.3% of themhave an advanced degree, either amaster or a doctor-
ate degree following their graduation from medical school. Among this
population, the number of physicians participating in interventional op-
erations was up to 25.9%, however, only 10.2% of them have the qualiﬁ-
cations attestation (The examination of cardiovascular specialists and
the test of interventional diagnosis and treatment are required for qual-
iﬁcations). With respect to new workforce training, the data based on
China Statistic Almanac (2011) indicated that 6524 candidates for ad-
vanced doctor degree were recruited by medical colleges, whereas
33,543 for advanced master degree in 2010. Among them, one of the
largest groups, physicians are attending an advanced degree in popula-
tionmedicinewith a special concentration in cardiovascular diseases. In
Beijing and Shanghai, as a cardiovascular specialist, it usually requires
11 years in school training for their degrees (5 years for their bachelor
degree in medicine; 3 years for their advanced master degree in medi-
cine; and 3 years for their advanced doctoral degree in cardiovascular
medicine); and an additional 3 years clinical training in generalmedicine. Furthermore, in the top ranking cardiovascular centers, doc-
toral candidates will undergo intense hands-on training with various
procedures for up to 300 operations each year.
10. Conclusion
Over the past twenty years, Chinese cardiovascular medicine has
undergone a major paradigm shift; transforming its focus from
symptom-based therapy to life-style guided improvement. Prevention
in cardiovascular medicine has taken central stage; it has emerged to
coordinate efforts addressing all elements in the cascade of pathogene-
sis: from identiﬁcation of behavior and biological triggers, to character-
ization of markers indicative of occurrence of disease, disease
persistence, as well as its progression and recurrence. Ostensibly, to
combat cardiovascular diseases in China requires the continued support
of our government agencies; the innovation and advancement in
medicine; furthermore, it requires an active engagement of the general
public with their commitment and determination for a healthy and
strong nation.
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